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ABSTRACT Neutrophil-endothelial cell interactions
are mediated by interacting sets of cell adhesion
molecules (CAMs) and chemoattractant/activator
molecules to form an “adhesion cascade.” The initial
phase of inflammation, a transient slowing of neutrophils
in postcapillary venules, is mediated by selectins. Subse-
quently, firm adhesion of neutrophils to the vessel wall oc-
curs via interaction of the CD11/CD18 (/32) integrins to
endothelial ligands such as intercellular adhesion
molecule-i (ICAM-1). This binding requires activation of
CD11/CD18 by exposure of the neutrophil to a variety of
activating/chemoattractant molecules, such as platelet-
activating factor or interleukin-8. Finally, transmigra-
tion into tissues occurs, a process that requires both a
chemotactic stimulus and engagement of platelet-
endothelial cell adhesion molecule-i (PECAM-i). Several
approaches have been used to probe the role of CAMs in
vivo. These include the use of blocking antibodies, chi-
meric selectin-immunoglobulin proteins, sialyl Lewisx
oligosaccharides and peptides, along with the study of hu-
mans and animals with genetically determined adhesion
deficiencies. These studies demonstrate that CAM block-
ade can effectively inhibit inflammation; however, there
appear to be clear differences in the adhesion require-
ments for particular types of inflammation. By under-
standing the CAM/chemoattractant profiles involved in
specific disease states, it may be possible to precisely and
effectively target therapy to a wide variety of inflamma-
tory diseases.-Albelda, S. M., Smith, C. W., Ward, P. A.
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THE RECRUITMENT OF LEUKOCYTES INTO AREAS OF inflamma-
tion begins with the binding of white blood cells to en-
dothelium, followed by their transmigration into tissues.
Although this observation has been documented for more
than 150 years, only in the last decade, with the identification
of specific cell adhesion and chemoattractant/activator
molecules, have the molecular mechanisms underlying leu-
kocyte adhesion been uncovered. Three families of cell adhe-
sion molecules (CAMs)2 play a central role in leukocyte-
endothelial interactions: the selectins, the integrins, and the
immunoglobulin superfamily (1) (see Table 1). In addition,
factors that activate neutrophils or endothelial cells (Table
2), thereby resulting in CAM expression and/or chemotactic
migratory responses, are also important. It is now recog-
nized that these different types of CAMs and chemoattracts
interact in a programmed, sequential manner to form what
has been termed the leukocyte-endothelial cell adhesion cas-
cade (2-5). The purpose of this review is to summarize re-
cent information concerning the mechanisms by which leu-
kocytes (specifically, neutrophils) enter regions of inflammation
and how this information might be used to develop novel
therapeutic approaches.
THE ENDOTHELIAL CELL-LEUKOCYTE
ADHESION CASCADE
Most neutrophil emigration occurs in specialized regions of
the vascular tree, i.e., in postcapillary venules, and can be
divided into distinct phases (Fig. 1). When viewed with in
vivo microscopy (reviewed in ref 6), the first event (Fig. IB)
is the slowing or margination of the circulating leukocytes
within the venule where the white cells are only loosely
tethered to the vessel wall and roll along the surface of the
endothelium at velocities of less than 50 jem/s. After a varia-
ble period of rolling, many neutrophils firmly adhere to the
endothelial cell surface (Fig. 1C) and appear to become acti-
vated, changing from a spherical configuration to a flattened
shape. Aggregates of neutrophils and some attached platelets
are often seen. Adherent cells then migrate through the junc-
tions of endothelial cells and move to a region between the
endothelium and its basement membrane (Fig. 1D). After a
brief pause in this location, the neutrophils finally migrate
into the surrounding interstitial tissue. Each step of neu-
trophil emigration has been associated with specific CAMs
and CAM activators or chemoattractants.
Rolling
The initial phase of the adhesion cascade, neutrophil rolling,
is mediated by members of the selectin family. The selectins
(7, 8) include a group of three related molecules. L-selectin
(Lam-i, LECAM-1) is constitutively expressed on neu-
trophils and is shed from the cell surface on cell activation,
assumed to occur immediately after rolling begins (9). P-
selectin (GMPI4O or PADGEM) is found on platelets and is
stored in Weibel-Palade bodies where it is quickly (within
minutes) moved to the cell surface after endothelial cell acti-
vation by stimuli such as histamine, thrombin, bradykinin,
leukotriene C4 (LTC4), or free radicals. E-selectin (ELAM-i)
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2CAM, cell adhesion molecule; PECAM-i, platelet-endothelial
cell adhesion molecule; Ig, immunoglobulin; TNFa, tumor necro-
sis factor-a; IL-l, interleukin 1; LFA-l, lymphocyte function
antigen-I; PAF, platelet activating factor; IL-8, interleukin 8;
ICAM, intercellular adhesion molecule; VCAM-l, vascular cell
adhesion molecule-i; LTB4, leukotriene B4; LAD, leukocyte adhe-
sion deficiency; LPS, lipopolysaccharide.
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TABLE I. Leukocyte-endothelial cell adhesion receptors
Molecule Primary expression Ligand
Selectins
L-selectin PMN and lymphs CD34, GlyCAMia
P-selectin EC, platelet P-selectin glycoprotein ligand (PSGL-i)
Sialyl Lewis’ and others
E-selectin EC Sialyl Lewis’ and others
Integrins
LFA-i (CD11aJCD18)
Mac-i (CD11b/CD18)
PMN and lymphs
PMN
ICAM-i and ICAM-2
ICAM-i, and others6
VLA-4 (a4$, Integrin) Eos and lymphs VCAM-i, FN
Immunoglobulin superfamily
ICAM-i Lymphs and EC LFA-l, Mac-i
ICAM-2 Lymphs and EC LFA-I
VCAM-1 EC VLA-4
PECAM-i EC, PMN, lymphs, platelets PECAM, others
a Ligands for lymphocyte L-selectin; the ligands for neutrophil L-selectin have not yet been identified. MOther ligands for Mac-I include iC3b,
fibrinogen, and bacterial LPS. PMN, polymorphonuclear leukocyte; lymphs, lymphocytes; EC, endothelial cells; Eos, eosinophils.
is expressed solely on endothelial cells where it is synthesized
rapidly after cell stimulation by cytokines (TNFa, IL-i) or
endotoxin and then translocated to the luminal surface of the
venular endothelium.
Each selectin shares a common molecular structure, most
notably an NH2-terminal lectin-like domain, that imparts
the ability of each selectin to bind to specific carbohydrate
ligands. To date, three structures have been identified that
appear to have binding affinity for selectins: 1) oligosaccha-
rides related to sialyl Lewis” and sialyl Lewisa; 2) phos-
phorylated mono- and polysaccharides; and 3) sulfated poly-
saccharides and lipids (7). It is still unclear which molecules
(in the form of glycoconjugates) present these carbohydrate
derivatives to the selectins as counter-receptors. Although
ligands for lymphocyte L-selectin on high endothelial yen-
ules have been identified and cloned (10), a similar ligand for
neutrophil L-selectin on activated endothelium has yet to be
TABLE 2. Neutrophzil and endothzelial cell activating factors
identified. One function of L-selectin may be to present
molecules of sialyl-Lewis” to E-selectin and P-selectin and
thus to serve as one of the counter receptors for selectins on
endothelial cells and platelets (ii, 12). Recently, Sato et al.
(13) used expression cloning to identify a mucin-like trans-
membrane glycoprotein that functions as a ligand for P-
selectin on myeloid cells when appropriately glycosylated
(termed P-selectin glycoprotein ligand or PSGL-1).
Activation and firm adhesion
Although rolling appears to be a prerequisite for eventual
firm adherence to blood vessels under conditions of flow (14),
selectin-dependent adhesion of leukocytes does not lead to
firm adhesion and transmigration unless another set of adhe-
sion molecules is engaged. For neutrophils, firm adhesion re-
quires activation of the /32 (CDI8) integrin family, resulting
Activating agent
Targets
Neutrophils Endothelial cells
Cytokines
Tumor necrosis factor a (TNFce)
Interleukin-i (IL-i)
TNFa
IL-i
Interleukin-4
Interferon-’y
Chemokines
Interleukin-8
GROa
Neutrophil-activating peptide-2
Platelet factor 4
Lipids
Leukotriene B4 (LTB4)
Platelet-activating factor (PAF)
Bacterial endotoxin
Other
Complement fragments (C5a)
f-Met-Leu-Phe (FMLP)
Thrombin
Histamine
H2O2
Bradykinin
Leukotriene C4 (LTC4)
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Figure 1. The endothelial cell-leukocyte adhesion cascade. Under
baseline conditions (A), neutrophils are nonadherent to the vessel
wall. The first event in white cell emigration is the slowing or rolling
of the circulating leukocytes within the venule mediated by selectins
(B). After a variable period of rolling, an activation event occurs
resulting in neutrophils firmly adhering to the endothelial cell sur-
face (C) and changing from a spherical configuration to a flattened
shape. This process requires interaction of activated CD18 integrins
on neutrophils with immunoglobulin superfamily members (i.e.,
ICAM-i) on the endothelium. Adherent cells then transmigrate
through the junctions of endothelial cells (D), an event that requires
a chemotactic gradient and involvement of the adhesion molecule,
PECAM-l. After a brief pause in this location, the neutrophil
finally migrates into the surrounding interstitial tissue.
in binding to one of the intercellular adhesion molecules on
the surfaces of endothelial cells.
The CDii/CD18 integrins, specifically CDi1aJCDI8
(LFA-i) and CD11b/CD18 (Mac-i), were among the first cell
adhesion molecules to be identified and characterized (14,
15). As typical members of the integrin family, these
molecules are heterodimers composed of unique a subunits
noncovalently bound to a common /3 subunit (/32) (i).
Although both CDIIa and CDiib interact with the immuno-
globulin superfamily member, ICAM-i, CDlib is capable of
binding a wide range of ligands, including fibrinogen, dena-
tured albumin, and complement fragments (iC3b) (16), as
well as unidentified ligands on endothelial cells (17).
An important characteristic of the neutrophil integrins is
that under baseline conditions they exist in a relatively inac-
tive conformation, rendering the leukocyte nonadhesive.
One of the key events of the adhesion cascade is the activa-
tion (sometimes accompanied by the addition of protein on
the cell surface) and deactivation of these integrins at the
proper times and places. Evidence for a conformational
change associated with high avidity is found in the binding
of some monoclonal antibodies that appear to recognize epi-
topes found only in the activated or bound state of the inte-
grins (18, 19).
One important pathway by which integrin activation ap-
B I pears to occur is that neutrophils interact with stimulatoryase ifle molecules that are bound to the surfac of the endothe ium.
This idea is attractive for several reasons. First, it explains
how chemoattractants could act quickly enough to target leu-
kocyte migration before being swept downstream. Second,
most of the chemoattractant molecules, in addition to ac-
tivating integrins, also cause shedding of L-selectin and
stimulate neutrophil locomotion. Kishimoto et al. (9) pro-
Rolling posed that shedding of L-selectin may facilitate cell migra-
tion by releasing a potentially tethering adhesive mechanism
as neutrophils shift to /32 integrin-dependent migration. Lo-
cation and timing of this stimulation may be critical as, in
fact, many chemoattractant molecules have well-documented
leukocyte adhesion inhibitory activity when presented to
Activation neutrophils in soluble phase (20).
and Good evidence to support the importance of surface acti-
firm adhesion vation in white cell emigration has been presented for two
inflammatory mediators: platelet-activating factor (PAF)
and interleukin-8 (IL-8). PAF is synthesized by endothelial
cells within minutes after stimulation by thrombin, hista-
mine, LTC4, or other agonists, and is expressed on the cell
surface where it activates neutrophils and up-regulates
CDlib by binding to a specific cell-surface receptor (21).
Many of the same factors that stimulate PAF expression also
cause rapid translocation of P-selectin to the surface of the
endothelium (see above). Thus, for at least one set of stimuli
both a specific tethering molecule (P-selectin) and a specific
activator molecule (PAF) are produced. A similar situation
may exist for the neutrophil chemoattractant/activator IL-8.
IL-8 appears to bind to the luminal surface of activated en-
dothelial cells where it is able to activate neutrophils (22).
Because cytokines, such as TNFa, and other factors (such as
endotoxin) cause the synthesis of both IL-8 and E-selectin
from endothelial cells (23), it is likely that these mediators
may augment neutrophil transmigration by stimulating ex-
pression of both the tethering molecule and the activating
factor (24).
Important ligands for the CD11/CDi8 integrins are
ICAM-i, and possibly ICAM-2 (reviewed in ref 21). These
molecules, members of the immunoglobulin superfamily, are
present constitutively on endothelial cells both in vitro and
in vivo. CDila and CDI1b bind to ICAM-1 in different
regions of the molecule. Only CDila has been shown to be
capable of binding to ICAM-2. Constitutive expression of
endothelial ICAM-2 is relatively stable, whereas ICAM-i ex-
pression can be augmented by a variety of inflammatory
mediators including TNF, IL-I, -y-interferon, and endotoxin.
The increase in expression is dependent on protein synthesis
and peaks about 8 h after stimulation in both in vitro (2) and
in vivo models (25). Monoclonal antibody blocking experi-
ments suggest that ligands in addition to ICAM-1 may be
important in neutrophil-endothelial interactions (5, 26).
Even with the relatively high levels of ICAM-i on resting en-
dothelium, it appears that the additional expression induced
by cytokines is important in neutrophil-endothelial interactions.
Transmigration
Transendothelial cell migration does not necessarily accom-
pany leukocyte adherence to the endothelium. Although
chemotactic factors, such as LTB4, C5a, and f-Met-Leu-Phe,
can augment leukocyte adhesion to endothelium (reviewed
in ref 27), transmigration across an endothelial monolayer
requires a chemotactic gradient (28). Spontaneous trans-
Transmigration
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migration of neutrophils through TNFa- or IL-I-stimulated
endothelial monolayers has been observed (29, 30); however,
it is likely that these cytokines also cause expression of potent
chemotactic stimuli such as IL-8 (24), which for the reasons
cited above, affect both adherence and transmigration of
neutrophils.
Recent studies have implicated another adhesion molecule,
platelet-endothelial cell adhesion molecule-i (PECAM-i), in
transmigration. PECAM-1, a member of the immunoglobu-
un superfamily, is expressed at relatively low levels on the
surface of leukocytes and platelets but at higher levels (>106
molecules per cell) on endothelium (31). Its localization at
the junctions between endothelial cells has suggested a role
in transendothelial cell migration. Using an in vitro model,
Muller et al. (30) demonstrated that antibodies against
PECAM-1 significantly blocked leukocyte transmigration
through TNFa-activated endothelial cell monolayers but did
not affect the adhesion of neutrophils. This effect has re-
cently been confirmed in animal models of neutrophil trans-
migration (32). The mechanisms by which PECAM-1 may
regulate transendothelial migration are not yet known;
however, the possibilities include direct binding of PECAM-i
to the leukocyte (perhaps serving as a molecular guide as it
passes through the junction), or regulation of adhesion
molecules on the surface of the leukocyte (i.e., /32 integrins),
thus facilitating transmigration (30). Available data indicate
that cross-linking of PECAM-i on the surface of leukocytes
by antibodies can up-regulate integrin-mediated binding (33).
Another process that may play an important role in tran-
sendothelial migration is the ability of the endothelial cell
monolayer to regulate an opening of its junctions, allowing
neutrophil transmigration. Recent work by Huang et al. (34)
suggests that transmigrating neutrophils (in response to a
chemotactic stimulus) exert an active influence on the en-
dothelial cell monolayer, resulting in increased intracellular
endothelial calcium levels and opening of intercellular junctions.
NONCASCADE DEPENDENT LEUKOCYTE
EMIGRATION
As a general rule, neutrophil transmigration appears to be
preceded by endothelial activation (defined by up-regulation
of adhesion molecules). However, this cascade may not be
operative during all types of inflammatory reactions. Several
chemoattractant/activators are able to directly up-regulate
neutrophil CDilb/CDI8 activity and allow adhesion of the
leukocytes to resting, unactivated endothelial cells (perhaps
by binding to constitutively expressed ICAM-i) without ap-
parent involvement of selectins. This process is also probably
operative in vivo (4). It thus seems likely that in vascular
beds where blood flow is diminished (by geometric con-
straints or by vascular occlusion/vasoconstriction), activation
of the CD18 integrins, along with the presence of a
chemotactic gradient, may be sufficient for neutrophil trans-
migration, without additional activation of endothelium.
This mechanism may be operative in clinical situations, such
as sepsis, where intravascular activation of neutrophils leads
to neutrophil sequestration in the lung and other organs.
Another process that may be an accessory means of
localizing additional neutrophils at the early stages of inflam-
matory reaction is neutrophil aggregation. This represents
both homotypic aggregation between neutrophils, a
phenomenon that has been shown in vitro to be primarily a
CDlib-dependent event (35), and heterotypic aggregation
between neutrophils and platelets, an event primarily depen-
dent on P-selectin, at least in vitro (36).
INFLAMMATION AND THE ADHESION CASCADE
Because of the complexity and diversity of the inflammatory
response, it has been increasingly important to evaluate the
role of cell adhesion molecules in animal models of specific
inflammatory events. Probing the role of adhesion molecules
involved in in vivo inflammatory responses has taken several
different approaches. One strategy has been to infuse soluble
forms of CAMs to compete with naturally occurring in vivo
selectin molecules and inhibit neutrophil accumulation (37,
38). These studies have, for the most part, used chimeric
selectin-Ig proteins (which contain the extracellular portions
of selectins fused to the CH2 and CH3 domains of the IgG
heavy chain), as these hybrids have a longer half-life than
soluble forms of selectins when infused intravenously. The
infusion of an L-selectin chimera significantly inhibited the
number of neutrophils migrating to the peritoneum in
response to an inflammatory infiltrate (37). In rat models, L-
and P-selectin chimeras blocked complement-mediated lung
injury, whereas L- and E-selectin chimeras inhibited im-
mune complex-induced lung damage (38). A related
strategy, shown to be useful in the case of either E-selectin
or P-selectin-dependent inflammatory reactions, involves the
infusion of sialyl Lewis” oligosaccharides (the penta and
tetra versions) that appear to compete with selectin-
dependent binding interactions (39). It may also be possible
to design peptides that simulate the binding site of an adhe-
sion molecule. To date, this has been chiefly used to interfere
with P-selectin (40) or CDIib-dependent reactions in vitro
(41). The applicability of these peptides in vivo remains to be
determined.
Another approach that has yielded a great deal of infor-
mation about the in vivo role of adhesion molecules has been
the study of animals (or humans) in which there is a natur-
ally occurring or artificially induced CAM defect. Some of
the earliest clues suggesting the clinical importance of cell
adhesion molecules came from the study of congenitally ac-
quired syndromes featuring impaired host defenses against
bacterial pathogens. Leukocyte adhesion deficiency (LAD)
type I (reviewed in ref 15) is characterized by a profound
defect in phagocyte emigration, chronic neutrophilia, and
recurrent infections without formation of pus, and is due to
a deficiency of members of the CDI1/CDi8 family of adhe-
sion molecules on neutrophils as a result of a number of
different mutations. Neutrophils isolated from LAD-type I
patients show normal rolling behavior, but are incapable of
sticking to endothelial monolayers or emigrating in response
to chemotactic stimuli. The recently described LAD-type II
(42) is characterized by a very similar clinical scenario;
however, molecular analysis has revealed that this syndrome
is due to a congenital defect of endogenous fucose
metabolism. This results in an inability to synthesize
fucosylated carbohydrate molecules, such as sialyl Lewis”,
and a crippled selectin system. Consistent with predictions,
neutrophils isolated from LAD type II patients are able to
adhere normally to activated endothelial monolayers under
static conditions but show marked defects in rolling and ad-
herence under shear force (43).
More recently, it has been possible to begin to explore the
role of leukocyte-endothelial cell molecules in inflammation
by studying mice engineered using homologous recombina-
tion techniques to lack specific CAMs. Wilson et al. (44)
have developed mice that express only 2-16% of the normal
levels of CDI8 expression on granulocytes. These animals
show an impaired inflammatory response to a chemical
peritonitis and delayed rejection of cardiac grafts. “Knock-
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outs” of two of the immunoglobulin superfamily cell adhe-
sion molecules have also recently been achieved. Mice
deficient in VCAM-1 expression are not viable and die in
utero due to cardiac and other developmental abnormalities
(45). In contrast, mice deficient in ICAM-i (46) develop nor-
mally, are fertile, and appear normal except for a moderate
granulocytosis. However, these ICAM-1-deficient animals
exhibit impaired neutrophil emigration in response to chem-
ical peritonitis and decreased contact hypersensitivity to 2,4,
dinitrobenzene. In addition, leukocytes from these mice pro-
vide negligible stimulation for the mixed lymphocyte reac-
tions. Mice lacking P-selectin (47) develop normally;
however, they exhibit a striking leukocytosis, diminished roll-
ing of leukocytes in mesenteric vessels, and delayed recruit-
ment of neutrophils to the peritoneal cavity after experimen-
tally induced peritonitis. E-selectin-deficient mice (45) have
a similar phenotype with regard to delay in neutrophil
recruitment into experimentally induced peritonitis, but do
not have leukocytosis. Administration of anti-P-selectin anti-
body to the E-selectin knockout mice completely blocks neu-
trophil recruitment, suggesting that in this model some
redundancy of function may exist between the two en-
dothelial cell selectins. The degree of immune deficiency in
most of the knockout animals is not as severe as in humans
and bovines with the severe form of LAD I deficiency who
naturally acquire acute life-threatening bacterial infections
at an early age. Early deletion of a specific CAM may allow
alternative pathways to develop. A significant problem in
evaluation of the gene knockout animals maintained in bar-
rier facilities is the need to apply highly quantitative and
reliable techniques for the in vivo measurement of possible
changes in expression of the inflammatory response.
Much of our knowledge about the role of CAMs in inflam-
mation has come from the use of blocking antibodies. This
approach has not been entirely straightforward, however, be-
cause of the inability of many well-characterized blocking
antibodies to cross-react in animals species, the tendency of
some antibodies (i.e., anti-L-selectin) to induce neutropenia,
and interactions by the Fc portion of some antibodies neces-
sitating the use of F(ab’)2 fragments (48). Nevertheless, these
difficulties have been solved in different ways, including care-
ful screening of known bioactive human monoclonal anti-
bodies against a variety of animal species and looking for
cross-reactivity (e.g., ref 48), the generation of rodent-
specific bioactive antibodies, and by transplantion of human
tissues into immunodeficient mice (25).
Selectins
The role of L-selectin in neutrophil transmigration in vivo
was first demonstrated by Jutila et al. (49), who showed that
an antibody (MEL-14) against the murine form of L-selectin
could suppress neutrophil accumulation within the inflamed
peritoneum of a mouse by about 70%. Ley et al. (50), using
intravital microscopy, directly demonstrated a decrease in
the number of neutrophils undergoing rolling within rat
mesenteric venules after administration of a polyclonal anti-
L-selectin antibody.
Despite a great deal of in vitro work indicating that E-
selectin is important in neutrophil-endothelial cell adhesion
(reviewed in ref 7), the lack of cross-reacting antibodies has
limited in vivo experiments. There are only a few reports
demonstrating blockade of white cell emigration by inhibi-
tion of E-selectin function in an intact animal. Mulligan et
al. (48) were able to block neutrophil migration into
glycogen-induced peritoneal exudates and immune complex-
induced skin and lung inflammation with a murine anti-
human E-selectin antibody discovered to cross-react with rat
E-selectin. Gundel et al. (51) were able to inhibit the influx
of neutrophils associated with the late-phase airway inflam-
mation in a primate model. Antibodies against human E-
selectin have recently been used to block white cell emigra-
tion in TNFa-activated human skin transplanted onto SCID
mice (52).
Similar problems with appropriate cross-reacting bioac-
tive antibodies have also hindered the understanding of the
physiologic role of P-selectin. Recently, however, inflamma-
tory reactions that appear to depend heavily on P-selectin in-
teractions have been identified. These include pulmonary
vascular injury secondary to intravenous complement activa-
tion (53) and ischemia/reperfusion injury (54, 55).
CD11/CD18
The development of monoclonal antibodies with the ability
to block CD1Ia, CD1Ib, and/or CDI8 function in animals
without causing neutropenia has allowed many experiments
to be performed examining the role of CDI8 in inflammation
(the reader is referred to several excellent reviews [5, 6] that
discuss this topic in detail). Of all the adhesion molecules
studied to date, CD18 seems to have the most wide-ranging
and powerful effects. Blockade of the CD1I/CDI8 complex
has been shown to inhibit neutrophil influx in almost every
system tested to date, including skin, peritoneum, synovium,
lung, kidney, and heart. Accordingly, intravenous applica-
tion of anti-CDI1/CDI8 antibodies have been shown to
reduce inflammation and injury in models of allograft rejec-
tion, endotoxic and hemorrhage shock, hypersensitivity
reactions, bacterial meningitis, aspiration lung injury, pneu-
monia, and ischemia reperfusion. There are a few examples
where both CD18-dependent and CD18-independent path-
ways of neutrophil emigration have been identified, includ-
ing certain types of lung inflammation (56) and the late
movement of neutrophils into inflammed peritoneum (57).
ICAM-1
As one of the primary ligands for the CD18 integrins, it
would be expected that blockade of ICAM-1 would inhibit
the inflammatory response. Some studies (again, see ref 6 for
review) have shown effects of ICAM-I antibodies in various
models of inflammation such as transplant rejection, delayed
hypersensitivity, asthma, ischemialreperfusion, and immune
complex injury.
CELL ADHESION MOLECULE INVOLVEMENT
DEPENDS ON THE ORGAN AND THE NATURE OF
THE INFLAMMATORY STIMULUS: LESSONS FROM
INFLAMMATORY ANIMAL MODELS
One of the most important lessons that has emerged from
animal studies of CAMs is that there are distinct differences
in the adhesion requirements for particular types of inflam-
mation. This point is clearly illustrated by comparing a ser-
ies of studies by Mulligan et al. (38, 39, 48, 53, 58-62) con-
ducted in well-characterized rat models of inflammation. In
these experiments, summarized in Table 3, the effects of bi-
oactive antiadhesion molecule antibodies or selectin-Ig
chimeras on the intensity of tissue injury in four different
models of inflammation are compared. Whereas anti-CDI8
antibodies are effective in blocking all forms of neutrophil-
dependent inflammation, there seem to be differential con-
tributions of CD1Ia vs. CD1Ib. Another interesting differ-
ence is that the selectin requirements of various inflamma-
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TABLE 3. Differences in cell adhesion requirements in rat models of inflammation
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Inflammatory model
Reduction ( %) in Inflammatory Injury by antibody or se lectin-chimera blockade’
P-selectin E-selectin CD18 CDI la CD1 lb ICAM-l VLA-4
IgG immune complex lung injury
IgA immune complex lung injury
Systemic complement activation-related lung
IgG immune complex-induced glomerulitis
injury (CVF)
0
5(n. s.)
47
0
95
li(n. s.)
0
0
71 63
89 36
69 30
64 0
i5(n. s.)
63
53
46
61
61
72
55
40
77
0
37
‘As measured by vascular permeability or hemorrhage in the case of lung injury and proteinuria (24 h) in the case of glomerulonephritis. Except
as designated by n. s. (not significant), all values were statistically significant (P < 0.05). See refs 38, 39, 48, 53, 58-62 for details.
tory models, even within the same organ system, are quite
different. For example, E-selectin expression is up-regulated
in the pulmonary vasculature after intratracheal instillation
of lipopolysaccharide (LPS), IL-I, TNFa, or deposition of
IgG immune complexes (Fig. 2). Accordingly, antibodies to
E-selectin blocked neutrophil influx and tissue injury in IgG
immune complex-mediated lung disease (48). However, anti-
E-selectin antibodies had no effect on IgA-mediated immune
complex lung disease, a model where tissue macrophages
seem to play a dominant role (59). It is hoped that as more
models of injury are carefully studied, a set of rules will
emerge that will define which combination of cell adhesion
molecules, cytokines, and chemoattractants is involved in
specific disease states.
THERAPEUTIC APPROACHES
Interruption of the leukocyte-endothelial cell cascade has be-
come a major focus of anti-inflammatory research. Several
approaches are being developed. The blockade of CAM
function by use of specific blocking monoclonal antibodies is
one strategy. For example, anti-LFA-i monoclonal antibodies
have been used to prevent graft failure in patients receiving
HLA-mismatched bone marrow transplants (63). Clinical
trials are currently under way using anti-ICAM-i antibodies
to inhibit kidney allograft rejection (64). Obviously, the use
of monoclonal antibodies in the treatment of human diseases
will be limited by the generation of antimurine antibodies by
the recipient. However, the use of monoclonal antibodies
may be useful for problems that would benefit from short-
term therapies, such as acute transplant rejection, preven-
tion of ischemia reperfusion injury, or in well-defined epi-
sodes of sepsis or tissue injury. Humanization of murine an-
tibodies may provide some advantage by limiting the
production of antimurine antibodies.
Because of problems such as immunogenicity, the poten-
tial for causing immune complex disease, and requirements
for intravenous administration, a number of alternative ways
to inhibit cell adhesion molecules, are being explored. Solu-
ble forms of adhesion molecules represent one such ap-
proach. Neutrophil influx has been inhibited in vitro with
soluble P-selectin (65) and in murine and rat models using
soluble selectin-IgG chimeras (37, 38). Unfortunately, the
bioactivity of other soluble recombinant adhesion receptors,
E-selectin for example (66), seems to be quite low. The
difficulty in preparing large quantities of these receptors and
the requirement for intravenous delivery further limit their
potential utility. As mentioned above, the creation of peptide
mimetics of active binding regions of CAMs is also being ex-
plored. Short peptides based on sequences of ICAM-I (4i,
67), P-selectin (40), and PECAM-i (68) have been shown to
block certain in vitro adhesion events and could potentially
be useful in animal models.
Of more practical use would be small molecular weight
compounds with the potential for oral administration. The
discovery that selectin-mediated adhesion is dependent on
carbohydrate binding has generated a great deal of interest
in creating bioactive and biostable analogs of sialyl-Lewis”
or related sugars (see ref. 69 for example). Recent work in
rat models of inflammation (39) have demonstrated the ther-
apeutic feasibility of this strategy. Another approach that
holds promise is the use of antisense oligonucleotides
directed at cell adhesion molecules. Bennett et al. (70) have
been able to design oligonucleotides that selectively inhibit
the expression of ICAM-1, VCAM-i, and E-selectin in hu-
man endothelial cells, as well as block leukocyte adhesion to
TNF-stimulated endothelium in vitro. Preliminary studies
indicate that an antisense oligonucleotide directed toward
murine ICAM-i exhibits anti-inflammatory activity in
several mouse models of inflammation (71).
Finally, several agents appear to inhibit integrmn-mediated
white cell adhesion by unknown mechanisms. A partial list-
ing of such compounds would include PGE1 (72), lipoxin A
(73), nitric oxide (74), adenosine (75), and dapsone (76).
One of the most promising new families of molecules are the
leumedins, a new class of anti-inflammatory compounds
whose only known mechanisms of action to date is blockade
of integrin /32 function (77). One of these compounds has
been effective in increasing survival in endotoxin-treated
mice (78). The clinical applications of these new therapeu-
tics, along with agents designed to inhibit chemoattractant
molecules and cytokines (79), will doubtlessly be tested in the
near future.
CONCLUSIONS
Our understanding of the mechanisms of leukocyte emigra-
tion into areas of inflammation has increased dramatically in
the past decade. New adhesion molecules have been
identified. The physiological and pathophysiological roles
played by these molecules are rapidly being determined,
along with the realization that certain subsets of adhesion
molecules may be important in specific forms of inflamma-
tion. The complex relationships between adhesion molecules,
cytokines, and chemoattractants are also of active interest.
This knowledge has generated expectations that strategies
designed to inhibit cell adhesion will lead to novel and clini-
cally useful forms of anti-inflammatory treatments. This
goal is likely to be realized first in acute, self-limited dis-
orders amenable to treatment by intravenous infusion, such
as ischemiaireperfusion injury or early organ transplant re-
jection. By understanding the precise CAM/chemoattractant
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Figure 2. Pulmonary vascular expression of E-selectin. Panels A-D represent immunoperoxidase staining of frozen sections of rat lung
for E-selectin using a cross-reacting anti-human E-selectin monoclonal antibody. Normal lung (A), lungs after intratracheal instillation
of lipopolysaccharide (B), murine IL-i (C),and murine TNFa (D). Panels E and F are rat pulmonary artery endothelial cells in culture
stained for E-selectin: untreated endothelial cells (E); endothelial cells treated for 4 h with TNFa (F). (A-D, x 200: E, I x 400) (Mulligan,
M. S., and Ward, P. A., unpublished results).
profiles involved in specific disease states, it may be possible
to more precisely target therapy for use in long-term therapy.
For example, if the combination of molecules that result in
eosinophil infiltration were known, it might be possible to
design a more effective therapy for asthma. Selective target-
ing of antiadhesion therapy to defined anatomic regions,
such as delivery of a drug by inhalation or by instillation into
an affected joint space, could also be a useful alternative.
Critically important will be the identification organ or
disease-specific CAMs. Endothelial proteins that target sub-
sets of lymphocytes to the skin or certain subsets of lymph
nodes (80) have been recognized and raise the possibility that
other such organ-specific homing receptors might also exist.
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